Lyra Therapeutics (LYRA) Operating Margin (2021 - 2025)
Historic Operating Margin for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to 24948.0%.
- Lyra Therapeutics' Operating Margin fell 185674900.0% to 24948.0% in Q3 2025 from the same period last year, while for Sep 2025 it was 3780.73%, marking a year-over-year increase of 106751500.0%. This contributed to the annual value of 4308.09% for FY2023, which is 1770500.0% down from last year.
- As of Q3 2025, Lyra Therapeutics' Operating Margin stood at 24948.0%, which was down 185674900.0% from 4822.95% recorded in Q2 2025.
- Lyra Therapeutics' 5-year Operating Margin high stood at 860.98% for Q4 2024, and its period low was 137772.73% during Q4 2022.
- Moreover, its 5-year median value for Operating Margin was 4822.95% (2025), whereas its average is 18018.46%.
- Its Operating Margin has fluctuated over the past 5 years, first plummeted by -1327402500bps in 2022, then soared by 1264871100bps in 2023.
- Quarter analysis of 5 years shows Lyra Therapeutics' Operating Margin stood at 5032.47% in 2021, then plummeted by -2638bps to 137772.73% in 2022, then skyrocketed by 92bps to 11285.62% in 2023, then surged by 108bps to 860.98% in 2024, then plummeted by -2998bps to 24948.0% in 2025.
- Its Operating Margin was 24948.0% in Q3 2025, compared to 4822.95% in Q2 2025 and 4831.15% in Q1 2025.